Subscribe to our Newsletters !!
The safety and quality of produced medicines is ex
In the current technologically-driven Pharma and b
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Can gene editing be used as a life-saving treatmen
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
Glythera a UK based Biotechnology Compamy announces the appointment of Dr. Robert Lutz as a Chief Scientific Officer (CSO).
With more than 25 years’ experience, Dr Lutz was previously Vice President of Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers, pharmacology and toxicology departments.
The Company CEO Dr Dave Simpson Said,“Robert Lutz’s experience in ADC development will be a great asset as Glythera continues to develop our pipeline of cancer treatments.
With Robert’s appointment as CSO, and the addition of Jon Roffey to our Scientific Advisory Board, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat. ”
For more information: Click here
